Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
R

New Vulnerabilities in BRCAm Cancers

By Dana-Farber Cancer Institute FEATURING Roger Greenberg
By Dana-Farber Cancer Institute FEATURING Roger Greenberg
48 views
March 9, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

14:18
Incyte

Early Intervention in Chronic GVHD: Evaluating Efficacy and Safety O…

Feat. H. Ali

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Breast
15:34

SABCS 2024 Insights: BWEL Trial - Impact of Weight Loss Intervention…

2024 SABCS Annual Meeting Insights Hub

J. Ligibel

43 views
08:33

Management of HER2+ mBC: Treatment Decisions After T-DXd Progression

Dana-Farber Cancer Institute

G. Nader-Marta

113 views
12:22

SABCS 2024 Summary: Next-Generation SERDs and Their Clinical Applica…

2024 SABCS Annual Meeting Insights Hub

R. Jeselsohn

243 views
14:52

SABCS 2024 Summary: Evolution of SERDs - Limitations of Fulvestrant …

2024 SABCS Annual Meeting Insights Hub

R. Jeselsohn

64 views
07:58

SABCS 2024 Insights: Tumor-Infiltrating Lymphocytes and Response to …

2024 SABCS Annual Meeting Insights Hub

M. Tesch

83 views
01:56

SABCS 2024 Insights: Valemetostat + T-DXd in Previously Treated, Unr…

2024 SABCS Annual Meeting Insights Hub

S. Tolaney

11 views
02:18

SABCS 2024 Insights: EmpowHER 303 - Zanidatamab vs. Trastuzumab + Ch…

2024 SABCS Annual Meeting Insights Hub

S. Tolaney

30 views
02:25

ESMO 2024 Insights: Quantitative High Sensitivity HER2 Testing With …

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

374 views
02:49

ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarc…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

252 views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

1.8K views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.5K views
08:07

ASCO® 2024 Insights: "SACI-IO HR+ Trial - Sacituzumab Govitecan +/- …

2024 ASCO® Annual Meeting Insights Hub

A. Garrido-Castro

285 views
06:10

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs With t…

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney

860 views
08:18

ESMO Breast 2024 Insights: "Is There a Role for Combining PARP Inhib…

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney

337 views
05:35

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Role for…

Insights from ESMO Breast 2024 Annual Meeting

S. Tolaney

531 views
21:20

Older Adults With Breast Cancer: Research Updates

Dana-Farber Cancer Institute

R. Freedman

273 views
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views
22:34

What's New in Breast Cancer?

Dana-Farber Cancer Institute

S. Tolaney

1.6K views
17:35

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HER2CLIMB-0…

Insights from 2023 SABCS

P. Tarantino

1.1K views
17:20

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-75…

Insights from 2023 ESMO Annual Meeting

P. Tarantino

2.1K views
12:50

Expert Perspectives in the Management of TNBC

Oncology Data Advisor

S. Tolaney

757 views
09:32

ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysis - S…

Insights from 2023 ASCO® Annual Meeting

S. Tolaney

713 views
04:28

ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant Sacit…

Insights from 2023 ASCO® Annual Meeting

S. Tolaney

2.3K views
12:48

ASCO® 2023 Insights: "Association of Tumor-Infiltrating Lymphocytes …

Insights from 2023 ASCO® Annual Meeting

M. Tesch

124 views
11:01

Updates on the Personalized Management of HER2+ eBC for 2023

Dana-Farber Cancer Institute

A. Waks

94 views
14:11

ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion0…

ESMO Breast Cancer 2023 Congress Coverage

P. Tarantino

775 views
31:07

Supporting Older Adult Cancer Survivors With a Focus on Breast Cancer

Dana-Farber Cancer Institute

R. Freedman

84 views
39:42

Probing Genome Maintenance Mechanism Through the Lens of BRCA1/2 Syn…

Dana-Farber Cancer Institute

D. Durocher

77 views
33:37

PARPi in Ovarian Cancer: Maximizing Risk/Benefit Ratio

Dana-Farber Cancer Institute

E. Swisher

203 views
33:35

Advances in the Systemic Treatment of BRCA1/2 and PALB2-Associated B…

Dana-Farber Cancer Institute

F. Lynce

102 views
38:50

New Vulnerabilities in BRCAm Cancers

Dana-Farber Cancer Institute

R. Greenberg

48 views
29:11

Redefining BRCAness and Chemotherapy Response

Dana-Farber Cancer Institute

S. Cantor

20 views
36:28

Complexities of Utilizing Immunotherapy in BRCA-Associated Cancers

Dana-Farber Cancer Institute

J. Guerriero

128 views
34:05

Dana-Farber Cancer Institute 2022 SABCS Updates on mBC

Dana-Farber Cancer Institute

H. Burstein

195 views
13:32

Impact of DESTINY-Breast04 Data in HER2-Low Breast Cancer: How to Im…

Dana-Farber Cancer Institute

P. Tarantino

969 views
06:04

Updated Exploratory Analysis of the HER2CLIMB Trial for HER2+ mBC Wi…

Dana-Farber Cancer Institute

N. Lin

389 views
06:53

SABCS 2022 Primary Results From the POSITIVE Trial: Interruption of …

ecancer

A. Partridge

596 views
05:45

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC: Fin…

SABCS 2022 Conference Coverage

S. Tolaney

1.9K views
02:31

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rat…

SABCS 2022 Conference Coverage

S. Tolaney

78 views
16:49

SABCS 2022 Inflammatory Breast Cancer: A Perfect Storm

SABCS 2022 Conference Coverage

F. Lynce

317 views
14:58

SABCS 2022 Poster Reviews of Special Populations: Male Breast Cancer

SABCS 2022 Conference Coverage

J. Pablo Leone

250 views
14:31

An Overview of Male Breast Cancer

Dana-Farber Cancer Institute

J. Pablo Leone

80 views
07:56

Aiming at a Tailored Cure for ERBB2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

170 views
04:19

ESMO 2021 Update on T-DXd +/- Pertuzumab vs. THP in 1L HER2+ MBC: DE…

Dana-Farber Cancer Institute

S. Tolaney

335 views
11:30

Optimizing Treatment of MBC: Predictive / Prognostic Biomarkers, Ove…

i3 Health

S. Tolaney, I. Bleiweiss, M. Ross

30 views
07:55

2021 ASCO Updates From eMonarcHER on HR+, HER2+, N+, High-Risk eBC: …

Dana-Farber Cancer Institute

S. Tolaney

380 views
09:08

Results from monarcHER Trial on CDK4/6 Inhibitors + ET: Can Abemacic…

Dana-Farber Cancer Institute

S. Tolaney

554 views
25:16

Endocrine Therapy in Advanced HR+/HER2- Beyond 2020: Addition of CDK…

Dana-Farber Cancer Institute

E. Mayer

1.5K views
07:38

2019 APHINITY Trial Update: Fewer Deaths Seen in Addition of Pertuzu…

Dana-Farber Cancer Institute

S. Tolaney

1.4K views
07:23

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

S. Tolaney

1.8K views
07:40

Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Br…

Dana-Farber Cancer Institute

S. Tolaney

5.5K views
07:43

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Dana-Farber Cancer Institute

S. Goel

925 views